Drug Trial Radar · NCT05989048
A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,414
Actual
Start
Nov 29, 2023
Primary completion
May 30, 2025
Study completion May 30, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn how safe and effective zavegepant is compared to placebo in the acute treatment of migraine in Asian adults. Migraine is a very painful headache with other associated symptoms such as nausea, photophobia and phonophobia. A placebo is a harmless treatment that has no medical effect. This study is seeking for participants who: * have at least 1 year of migraine history before entering the study. * have 2 to 8 migraine headache attacks of moderate or severe intensity in each of the 3 months before entering the study. * have less than 15 days with headaches in each of the 3 months before entering the study. The headaches could be either due to migraine or not. The participants in this study will receive zavegepant or placebo through intranasal route. Intranasal means medicine which is given through nose. Zavegepant or placebo will be taken if the participants have a migraine headache of moderate or severe intensity. The study will compare the experiences of people receiving zavegepant to those of the people receiving placebo. This will help see if zavegepant is safe and effective in Asian adults. Participants will be in this study for up to about 16 weeks. Participants will have 3 study visits at the study clinic and 1 through telephone contact.
Conditions
- Migraine
Interventions
ZavegepantDrug
The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.
PlaceboDrug
Single dose of matching placebo taken within Treatment Phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Pain Freedom at 2 Hours Post-doseTime frame: At 2 hours post-dose
- Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-doseTime frame: At 2 hours post-dose
Locations
61 sites in 3 countries. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China
Xuanwu Hospital Capital Medical University
Beijing, China
Chongqing University Three Gorges Hospital
Chongqing, China
The fourth people's hospital of chongqing
Chongqing, China
Shanghai East Hospital
Shanghai, China
Tianjin Union Medical Center
Tianjin, China
The Second People's hospital of Hefei
Hefei, Anhui, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First Medical Center of Chinese PLA General Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Hainan General Hospital
Haikou, Hainan, China
Renmin Hospital Of Wuhan University
Wuhan, Hebei, China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, China
People's Hospital of Zhengzhou
Zhengzhou, Henan, China
Wuhan Third Hospital
Wuhan, Hubei, China
Changsha Central Hospital
Changsha, Hunan, China
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
The Second People's Hospital of Lianyungang
Lianyungang, Jiangsu, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Wuxi People's Hospital
Wuxi, Jiangsu, China
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
The Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
The People's Hospital of Liaoning Province
Shenyang, Liaoning, China
The First People's Hospital of Yinchuan
Yinchuan, Ningxia, China
General Hospital of Ningxia Medical Hospital
Yinchuan, Ningxia, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Shaanxi Provincial People' Hospital
Xi'an, Shaanxi, China
Xian Gaoxin Hospital
Xi'an, Shaanxi, China
Xianyang Hospital of Yan'an University
Xianyang, Shaanxi, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Jinan Central Hospital
Jinan, Shandong, China
Affiliated Hospital of Jining Medical University
Jining, Shandong, China
Liaocheng people's Hospital
Liaocheng, Shandong, China
Qingdao Central Hospital
Qingdao, Shandong, China
People's Hospital of Rizhao
Rizhao, Shandong, China
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.